drugset / Trial / NCT05340257

A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS

NCT05340257

Phase 2 Withdrawn GlaxoSmithKline
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics, safety or tolerability through treatment emergent adverse event (TEAE) and to explore primary and secondary clinical response of treatment with Augmentin ES in pediatric population presenting with CAP and ABRS in Brazil.

Timeline

Start
2023-10-14
Primary completion
2024-07-08
Completion
2024-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified
Subject clavulanic acid Small molecule